Antivirals: Difference between revisions
ClaireLewis (talk | contribs) (→HAART) |
(Text replacement - "OR" to "'''OR'''") |
||
| Line 25: | Line 25: | ||
**[[Emtricitabine/tenofovir]] (Truvada) + raltegravir | **[[Emtricitabine/tenofovir]] (Truvada) + raltegravir | ||
**[[Emtricitabine/tenofovir]] + dolutegravir | **[[Emtricitabine/tenofovir]] + dolutegravir | ||
**Abacavir/lamivudine (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq) | **Abacavir/lamivudine (Epzicom) + dolutegravir '''OR''' abacavir/lamivudine/dolutegravir (Triumeq) | ||
**[[Emtricitabine/tenofovir]]/elvitegravir/cobicistat (Stribild) | **[[Emtricitabine/tenofovir]]/elvitegravir/cobicistat (Stribild) | ||
**[[Emtricitabine/tenofovir]] + ritonavir + darunavir | **[[Emtricitabine/tenofovir]] + ritonavir + darunavir | ||
Revision as of 00:12, 31 May 2017
Anti-herpetic agents
Anti-influenza agents
Adamantane Derivatives
Neuraminidase Inhibitors
Interferons
HAART
- HIV regimen that typically consists of combination of 2 nucleoside and/or non-nucleoside reverse transcriptase inhibitors PLUS a protease inhibitor, reverse-transcriptase inhibitor, or integrase inhibitor
- US DHHS first-line regimens
- Emtricitabine/tenofovir (Truvada) + raltegravir
- Emtricitabine/tenofovir + dolutegravir
- Abacavir/lamivudine (Epzicom) + dolutegravir OR abacavir/lamivudine/dolutegravir (Triumeq)
- Emtricitabine/tenofovir/elvitegravir/cobicistat (Stribild)
- Emtricitabine/tenofovir + ritonavir + darunavir
- WHO first-line regimen
- Emtricitabine/tenofovir/efavirenz (Atripla)
- Tenofovir + lamivudine + efavirenz